Scienture Holdings, Inc. entered into a securities purchase agreement with institutional investors to purchase 3,225,000 shares of common stock at $1.20 per share.
The gross proceeds for the offering are expected to be approximately $3.9 million before expenses.
The offering is expected to close on August 15, 2025, subject to customary closing conditions.
Offering Details
3,225,000 shares of common stock at $1.20 per share with gross proceeds of approximately $3.9 million.
Maxim Group LLC
Acting as the sole placement agent for the offering.
Registration Statement
Offering made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-289198).
Prospectus Details
Shares may be offered only by means of a prospectus supplement filed with the SEC.
- The offering provides an opportunity for Scienture Holdings to raise capital for future ventures and expansion.
- Partnering with institutional investors enhances the company's financial stability and credibility in the market.
The securities purchase agreement and registered direct offering mark a significant step for Scienture Holdings, Inc. towards expanding its pharmaceutical operations and bringing novel specialty products to market.